Illumina Launches GenomeStudio™ Data Analysis Software

Main Category: Genetics
Also Included In: IT / Internet / E-mail
Article Date: 21 Oct 2008 - 9:00 PDT

email to a friend   printer friendly   view / write opinions   rate article

Illumina, Inc. (NASDAQ:ILMN) today introduced GenomeStudio Software, a primary analysis software program designed to analyze both microarray and sequencing data. For researchers, GenomeStudio Software enables the correlation of biological variation across multiple applications and graphical display of the results. The flexibility of GenomeStudio Software also allows researchers to integrate with third-party software providers for advanced downstream analysis. GenomeStudio Software will be broadly available to researchers in November 2008.

Under an early access program, Illumina offered GenomeStudio Software to customers from both academic research institutes and genome centers around the world. Among them was Stephen Kingsmore's lab at the National Center for Genetic Research (NCGR), Richard Michelmore's lab at University of California, Davis, Andy Fire's Lab at Stanford University, Barbara Wold's lab at the California Institute of Technology, and James Hadfield's lab at Cancer Research UK-Cambridge Research Institute.

"The rate at which we can go from sample preparation to visualizing exon-level expression is staggering," said Greg May, Ph.D., Director of the Genome Center at NCGR. "GenomeStudio Software allows us to see meaningful changes in RNA processing and will allow us to further unravel the complexities of transcriptional regulation in complex conditions such as schizophrenia and sepsis, a blood poisoning disease."

In addition to algorithms for copy number variation detection, single-nucleotide polymorphism calling, and differential analysis, GenomeStudio Software contains tools for visualizing sequencing data that are fueled by a new and expanded version of Illumina's Genome Analyzer Analysis Pipeline. A new processing module known as CASAVA (Consensus Assessment of Sequence and Variation) allows users to detect sequence variants from one or more Genome Analyzer sequencing runs. These new features allow users to align reads directly to sequences representing processed RNAs, and identify and quantify genes, exons, and splice junctions. Results are imported directly into GenomeStudio Software for visual and graphical analysis.

"The flexibility of Illumina's technologies allows scientists to conduct a number of genome-wide research applications. When developing GenomeStudio Software, we focused on overall integration and ease-of-use for genomic researchers," said Scott Kahn, Chief Information Officer at Illumina. "Researchers need graphical results to interpret data across multiple applications. Careful performance optimization allows us to bring the point-and-click simplicity of a laptop or desktop system to problems that once required teams of informaticians and heavy computational hardware."

Advanced analysis of data can be completed using a growing number of third-party analysis applications. In 2007 Illumina launched Illumina Connect to ensure that an analysis workflow that includes multiple software applications is streamlined. Illumina Connect is a bioinformatics software partnership program established to advance data integration and analysis. As part of this program, vendors receive example data sets and data formats that can optimize their applications' analytical abilities to best mine data generated by Illumina's sequencing and microarray-based applications. Vendors create customized plug-ins to Illumina's GenomeStudio Software to help expedite the transfer of data between applications. To date, more than 30 commercial and academic partners have joined Illumina Connect. For more information about Illumina Connect, please visit http://www.illumina.com/illuminaconnect.

About Illumina

Illumina is a leading developer, manufacturer, and marketer of next-generation life-science tools and integrated systems for the analysis of genetic variation and biological function. Using our proprietary technologies, we provide a comprehensive line of products and services that currently serve the sequencing, genotyping, and gene expression markets, and we expect to enter the market for molecular diagnostics. Our customers include leading genomic research centers, pharmaceutical companies, academic institutions, clinical research organizations, and biotechnology companies. Our tools provide researchers around the world with the performance, throughput, cost effectiveness, and flexibility necessary to perform the billions of genetic tests needed to extract valuable medical information from advances in genomics and proteomics. We believe this information will enable researchers to correlate genetic variation and biological function, which will enhance drug discovery and clinical research, allow diseases to be detected earlier, and permit better choices of drugs for individual patients.

"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995: this release may contain forward-looking statements that involve risks and uncertainties. Among the important factors that could cause actual results to differ materially from those in any forward-looking statements are Illumina's ability (i) to develop and commercialize further our BeadArray™, VeraCode®, and Solexa® technologies and to deploy new sequencing, gene expression, and genotyping products and applications for our technology platforms, (ii) to manufacture robust instrumentation and reagents technology, together with other factors detailed in our filings with the Securities and Exchange Commission including our recent filings on Forms 10-K and 10-Q or in information disclosed in public conference calls, the date and time of which are released beforehand. We disclaim any intent or obligation to update these forward-looking statements beyond the date of this release.

Source
Peter J. Fromen
Illumina, Inc.